Great Lakes Advisors LLC Has $2.69 Million Stake in Zoetis Inc. $ZTS

Great Lakes Advisors LLC reduced its position in Zoetis Inc. (NYSE:ZTS) by 55.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,325 shares of the company’s stock after selling 20,042 shares during the quarter. Great Lakes Advisors LLC’s holdings in Zoetis were worth $2,688,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. 1248 Management LLC bought a new position in Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in shares of Zoetis in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC increased its stake in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock worth $42,000 after buying an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its position in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company’s stock worth $46,000 after buying an additional 164 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on ZTS. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Piper Sandler boosted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Stock Down 0.2%

Shares of NYSE ZTS opened at $149.45 on Thursday. The company has a 50 day simple moving average of $152.70 and a 200 day simple moving average of $157.56. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The firm has a market cap of $66.24 billion, a PE ratio of 25.72, a price-to-earnings-growth ratio of 2.40 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.